Literature DB >> 26017248

Dehydrocostus Lactone Inhibits Proliferation, Antiapoptosis, and Invasion of Cervical Cancer Cells Through PI3K/Akt Signaling Pathway.

Enping Jiang1, Xiwen Sun, Haixian Kang, Liping Sun, Weifang An, Yunhong Yao, Xinrong Hu.   

Abstract

OBJECTIVES: Recent studies found that dehydrocostus lactone (DHC), a traditional Chinese medicine in curing chronic ulcer and inflammation, can inhibit several type of tumor cells. The purpose of this study was to define the role of DHC on cervical cancer cells and to explore its mechanism of action.
METHODS: We used DHC alone or in combination with PI3K/Akt-specific inhibitor LY294002 (LY) to treat Hela cells [human papillomavirus (HPV)-18 positive] and C33a cells (HPV negative). The proliferation, apoptosis, and Akt activation were assessed. Cell invasive ability was assayed in transwell chambers.
RESULTS: We found that DHC significantly inhibited proliferation, antiapoptosis, and invasion of both cells, and reduced the level of p-Akt phosphorylation in these cells, in a dose- or time-dependent manner. In addition, these inhibitions of DHC were significantly strengthened by LY.
CONCLUSIONS: The result suggested that DHC plays a potent role in anticervical cancer in multiple biological aspects through PI3K/Akt signaling pathway, independently of HPV infection. This finding surely adds new knowledge to understand the role of DHC in fighting cancers.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26017248     DOI: 10.1097/IGC.0000000000000474

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Glycyrrhetinic acid protects H9c2 cells from oxygen glucose deprivation-induced injury through the PI3K/AKt signaling pathway.

Authors:  Liqin Wang; Yuyan Zhang; Haitong Wan; Weifeng Jin; Li Yu; Huifen Zhou; Jiehong Yang
Journal:  J Nat Med       Date:  2016-07-12       Impact factor: 2.343

2.  Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.

Authors:  Ledi Kuang; Yuedong He
Journal:  Int J Clin Exp Pathol       Date:  2020-01-01

3.  MiR-125 inhibited cervical cancer progression by regulating VEGF and PI3K/AKT signaling pathway.

Authors:  Ke Fu; Ling Zhang; Rui Liu; Qi Shi; Xue Li; Min Wang
Journal:  World J Surg Oncol       Date:  2020-05-30       Impact factor: 2.754

4.  Dehydrocostus Lactone Enhances Chemotherapeutic Potential of Doxorubicin in Lung Cancer by Inducing Cell Death and Limiting Metastasis.

Authors:  Wei Sheng; Hongyan Mao; Chuanxi Wang; Ning Yang; Zhe Zhang; Junqing Han
Journal:  Med Sci Monit       Date:  2018-11-02

5.  SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway.

Authors:  Rong Hu; Ming-Qing Wang; Wen-Bo Niu; Yan-Jing Wang; Yang-Yang Liu; Ling-Yu Liu; Ming Wang; Juan Zhong; Hai-Yan You; Xiao-Hui Wu; Ning Deng; Lu Lu; Lian-Bo Wei
Journal:  Cancer Cell Int       Date:  2018-11-14       Impact factor: 5.722

6.  MiR-137 inhibits cervical cancer progression via down-modulating Notch1 and inhibiting the PI3K/AKT/mTOR signaling pathway.

Authors:  Ying Gui; Lina Wang; Zhihong Huang
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.